While AML patients (n = 169) exhibit high expression of KIR activating receptors, especially KIR3DS1, normal subjects (n = 167) express KIR inhibitory receptors, especially KIR2DL1 and KIR3DL1. This evidence concerns the gene KIR3DL1 and acute myeloid leukemia.